Latest Clinical & Research News
Specialty: Oncology
With about 12,000 to 13,000 cases diagnosed in the United States each year, sarcomas are among medicine’s rarest cancers. Since many oncologists may only see one or two cases during their career, patients often struggle to find experienced providers. Read More
Investigators at Dana-Farber Brigham Cancer Center have uncovered a potentially serious flaw in the current standard of care for patients with positive pelvic node prostate cancer (pN1 PC). They found that adjuvant radiation therapy (aRT) is associated with a decreased risk of death compared with early salvage radiation therapy (sRT) in men with four or more positive lymph nodes. Moreover, the reduction increases by 8% for each additional positive pelvic lymph node found at surgery. Read More
Dana-Farber Brigham Cancer Center is world-renowned for its commitment to cutting-edge research. Over the years, its researchers have turned scientific discoveries into life-saving treatments, contributing to the development of 35 of 75 cancer drugs recently approved by the FDA for use in cancer patients. Read More
Over the last few decades, Dana-Farber Brigham Cancer Center has advanced the care and management of head and neck cancer patients through a collaborative, multidisciplinary approach. The team has focused on surgical innovations such as free flap reconstruction and minimally-invasive transoral robotic surgery to help patients recover their speech and swallowing functions while delivering highly effective and state-of-the-art therapeutic interventions. Advances in chemotherapy, immunotherapy, and radiation delivery techniques have clearly helped to improve patient outcomes. Read More
Joshua D. Bernstock, MD, PhD, in the Department of Neurosurgery at Brigham and Women’s Hospital, Gregory K. Friedman, MD, of the University of Alabama at Birmingham, and colleagues reviewed novel therapies that target oncometabolism and tumor immunometabolism.
Read More...
Brigham researchers found that miR-10b seems to regulate mRNA splicing, suggesting an exciting new approach to research not just in glioma but in cancer more generally.
Read More...
Break Through Cancer is a foundation that brings together elite cancer research centers to collaborate on and accelerate research, clinical trials and cures for deadly cancers, including glioblastoma multiforme. The Brigham’s Nathalie Y. R. Agar, PhD, and E. Antonio Chiocca, MD, PhD, discuss this ambitious undertaking.
Read More...
Brigham investigators are examining the link between the microbiota and colorectal cancer, including exploring how bariatric surgery changes the microbiome and the impact this connection may have on the development of colorectal cancer. James Yoo, MD, and Eric G. Sheu, MD, PhD, co-lead this new research initiative.
Read More...
Adam S. Kibel, MD, and Anna Plym, PhD, of the Division of Urology, and colleagues conducted the most comprehensive study to date on the role of inherited DNA damage response (DDR) genes in aggressive prostate cancer. They report high carrier frequency of DDR gene alterations in lethal cases irrespective of ancestry.
Read More...
Ali Abbas, MD, MPH, Christopher C. Thompson, MD, MSc, and colleagues report similar technical success rates for endoscopic ultrasound–guided gastroenterostomy (EUS-GE) and surgical gastrojejunostomy, despite more advanced cancer stage and worse performance status in the EUS-GE cohort.
Read More...